Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3
Submit an article Journal homepage
301
Views
30
CrossRef citations to date
0
Altmetric
Review

When is switching warranted among biologic therapies in rheumatoid arthritis?

Alan Reynolds Reynolds Clinical Sciences Ltd, 13 Ladywood, Eastleigh, Hampshire, SO50 4RW, UK; Reynolds Clinical Sciences Ltd, 13 Ladywood, Eastleigh, Hampshire, SO50 4RW, UK. [email protected]
,
Andrew S Koenig Pfizer Inc., Specialty Care Business Unit, 500 Arcola Road, Collegeville, PA, USA
,
Eustratios Bananis Pfizer Inc., Specialty Care Business Unit, 500 Arcola Road, Collegeville, PA, USA
&
Amitabh Singh Pfizer Inc., Specialty Care Business Unit, 500 Arcola Road, Collegeville, PA, USA
Pages 319-333 | Published online: 09 Jan 2014

References

  • Smolen JS, Aletaha D, Bijlsma JW et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69(4), 631–637 (2010).
  • Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50(5), 1400–1411 (2004).
  • Klareskog L, van der Heijde D, de Jager JP et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675–681 (2004).
  • St Clair EW, van der Heijde DM, Smolen JS et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432–3443 (2004).
  • Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 4, CD007848 (2009).
  • Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther. 11(Suppl. 1), S1 (2009).
  • Carmona L, Gómez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res. Ther. 8(3), R72 (2006).
  • Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res. Ther. 8(6), R174 (2006).
  • Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 59(2), 234–240 (2008).
  • Kievit W, Adang EM, Fransen J et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis. 67(9), 1229–1234 (2008).
  • Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann. NY Acad. Sci. 1173, 837–846 (2009).
  • Hetland ML, Christensen IJ, Tarp U et al.; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22–32 (2010).
  • Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(4), 583–589 (2011).
  • Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 73(6), 718–724 (2006).
  • Saag KG, Teng GG, Patkar NM et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762–784 (2008).
  • Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010).
  • Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69(Suppl. 1), i2–i29 (2010).
  • Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114–1123 (2005).
  • Cohen SB, Emery P, Greenwald MW et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793–2806 (2006).
  • Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516–1523 (2008).
  • Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10(3), 308–315 (2010).
  • Villeneuve E, Haraoui B. To switch or to change class-the biologic dilemma in rheumatoid arthritis. Nat. Rev. Rheumatol. 6(5), 301–305 (2010).
  • Smolen JS, Kay J, Doyle MK et al.; GO-AFTER Study Investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet 374(9685), 210–221 (2009).
  • Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49(12), 2313–2321 (2010).
  • Rémy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin. Exp. Rheumatol. 29(1), 96–103 (2011).
  • Rendas-Baum R, Wallenstein GV, Koncz T et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res. Ther. 13(1), R25 (2011).
  • Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 22(3), 321–329 (2010).
  • Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572–2581 (2004).
  • Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907–1915 (2003).
  • Maini RN, Taylor PC, Szechinski J et al.; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817–2829 (2006).
  • Finckh A, Ciurea A, Brulhart L et al.; Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann. Rheum. Dis. 69(2), 387–393 (2010).
  • Buch M, Dass S, Vital EM et al. Is switching to rituximab more effective than switching to an alternative tumour necrosis factor blocking therapy (TNF-BT) in patients with rheumatoid arthritis (RA) who have failed a previous TNF-BT? Single-centre cohort experience. Ann. Rheum. Dis. 68(Suppl. 3), 574 (2009).
  • Chatzidionysiou K, Carl C, van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs in an observational cohort: the SARASTRA study. Ann. Rheum. Dis. 68(Suppl. 3), 445 (2009).
  • Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 68(11), 1708–1714 (2009).
  • Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin. Rheumatol. 27(7), 927–932 (2008).
  • Walsh CA, Minnock P, Slattery C et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 46(7), 1148–1152 (2007).
  • Hutchinson D, Tier J, Soper S, Wilson G, Davis M. The conversion of infliximab to adalimumab in stable RA patients. Rheumatology 44(Suppl. 1), i72 (2005).
  • Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21(3), 211–215 (2009).
  • Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54(12), 3782–3789 (2006).
  • Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33(1), 31–36 (2006).
  • Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54(3), 711–715 (2006).
  • Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739–1745 (2009).
  • Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann. Rheum. Dis. 69(5), 817–821 (2010).
  • Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14), 1460–1468 (2011).
  • Cimzia® (certolizumab pegol) prescribing information. UCB, Inc., GA, USA (2011).
  • de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68(4), 531–535 (2009).
  • Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 70(2), 284–288 (2011).
  • Simponi® (golimumab) prescribing information. Janssen Biotech, Inc., PA, USA (2011).
  • Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J. Rheumatol. 33(12), 2398–2408 (2006).
  • Donahue KE, Gartlehner G, Jonas DE et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann. Intern. Med. 148(2), 124–134 (2008).
  • Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann. Rheum. Dis. 71(2), 225–230 (2012).
  • Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost–effectiveness. Health Technol. Assess. 10(42), 1–266 (2006).
  • Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20(2), 119–130 (2011).
  • Pavelka K, Závada J, Mann H, Chroust K, Burešová L, Vencovský J. Comparison of survival rates of TNFα antagonists in rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriatic arthritis in Czech national registry ATTRA. Ann. Rheum. Dis. 6(Suppl. 3), 525 (2010).
  • Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 61(5), 560–568 (2009).
  • Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum. 54(2), 600–606 (2006).
  • Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39(8), 1254–1255 (2004).
  • Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50(2), 372–379 (2004).
  • Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57(5), 756–761 (2007).
  • Tubach F, Salmon D, Ravaud P et al.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60(7), 1884–1894 (2009).
  • Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69(3), 522–528 (2010).
  • Dixon W, Hyrich K, Watson K, Lunt M, Symmons D. The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: results from the BSR biologics register (BSBR). Rheumatology 47(Suppl. 2), ii47 (2008).
  • Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7), 737–744 (2009).
  • Salmon-Ceron D, Tubach F, Lortholary O et al.; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 70(4), 616–623 (2011).
  • Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 49(7), 1215–1228 (2010).
  • Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 60(11), 3180–3189 (2009).
  • Mariette X, Tubach F, Bagheri H et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 69(2), 400–408 (2010).
  • Mariette X. Lymphoma, rheumatoid arthritis, and TNFalpha antagonists. Joint Bone Spine 77(3), 195–197 (2010).
  • Nair KV, Tang B, Van Den Bos J, Zhang V, Naim A, Rahman M. Comparing medical utilization and expenditures between switchers and non switchers for tumor necrosis factor inhibitors (anti-TNFs) in the treatment of rheumatoid arthritis. The American College of Rheumatology 71st Annual Scientific Meeting Program Book. Abstract CRC46 (2007).
  • Meissner B, Trivedi D, Rosenblatt L, You M, Hebden T. Health care costs associated with switching of biologic disease modifying anti-rheumatic drugs. J. Manage. Care Pharm. 17(7), 560 (2011).
  • Moots RJ, Haraoui B, Matucci-Cerinic M et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin. Exp. Rheumatol. 29(1), 26–34 (2011).
  • Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet. Disord. 5(1), 36 (2004).
  • Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin. Ther. 31(4), 825–835 (2009).
  • Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am. J. Health Syst. Pharm. 67(15), 1281–1287 (2010).
  • Combe B. Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. Clin. Exp. Rheumatol. 28(3 Suppl. 59), S13–S17 (2010).
  • Trivedi D, Rosenblatt L, Hebden T. Comparative cost–efficacy of biologic agents used to treat patients with rheumatoid arthritis. J. Manage. Care Pharm. 17(7), 554 (2011).
  • Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 46(8), 1345–1354 (2007).
  • Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost–effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J. Rheumatol. 36(1), 16–26 (2009).
  • Cimmino MA, Leardini G, Salaffi F et al. Assessing the cost–effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin. Exp. Rheumatol. 29(4), 633–641 (2011).
  • Russell A, Beresniak A, Bessette L et al. Cost–effectiveness modeling of abatacept versus other biologic agents in DMARDs and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin. Rheumatol. 28(4), 403–412 (2009).
  • Bombardieri S, Ruiz AA, Fardellone P et al.; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46(7), 1191–1199 (2007).
  • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244–279 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.